+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Enanta Pharmaceuticals Inc - logo

Enanta Pharmaceuticals is a biotechnology company that focuses on small molecule drugs for viral infections and liver diseases. Enanta’s research is currently focused on the following disease targets: Hepatitis B Virus (HBV), Non-alcoholic Steatohepatitis (NASH)/PBC and Respiratory Syncytial Virus (RSV). The company has a collaborative development and license agreement with AbbVie to develop and commercialize HCV NS3 and NS3/4A protease inhibitors. Enanta was founded in 1995 and is headquartered in Watertown, Massachusetts.

Liver Diseases Therapeutics Global Market Report 2024 - Product Thumbnail Image

Liver Diseases Therapeutics Global Market Report 2024

  • Report
  • February 2024
  • 200 Pages
  • Global
From
Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2024 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Non-Alcoholic Steatohepatitis (NASH) Disease - Global Clinical Trials Review, H1, 2021 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis (NASH) Disease - Global Clinical Trials Review, H1, 2021

  • Clinical Trials
  • February 2021
  • 469 Pages
  • Global
From
Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2020 - Product Thumbnail Image

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 319 Pages
  • Global
From
Respiratory Syncytial Virus (RSV) Infections - Global Clinical Trials Review, 2022 - Product Thumbnail Image

Respiratory Syncytial Virus (RSV) Infections - Global Clinical Trials Review, 2022

  • Clinical Trials
  • January 2022
  • 244 Pages
  • Global
From
Respiratory Syncytial Virus (RSV) Infections - Global Clinical Trials Review, H2, 2021 - Product Thumbnail Image

Respiratory Syncytial Virus (RSV) Infections - Global Clinical Trials Review, H2, 2021

  • Clinical Trials
  • November 2021
  • 224 Pages
  • Global
From
HBV Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type - Product Thumbnail Image

HBV Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type

  • Report
  • February 2024
  • 101 Pages
  • Global
From
Primary Biliary Cirrhosis Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Thumbnail Image

Primary Biliary Cirrhosis Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • February 2024
  • 98 Pages
  • Global
From
Non-alcoholic Steatohepatitis Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology - Product Thumbnail Image

Non-alcoholic Steatohepatitis Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology

  • Report
  • February 2024
  • 104 Pages
  • Global
From
Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028 - Product Thumbnail Image

Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028

  • Report
  • November 2019
  • 153 Pages
  • Asia Pacific
From
Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides & Customization. 2023 to 2027 - Product Thumbnail Image

Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides & Customization. 2023 to 2027

  • Report
  • May 2024
  • 449 Pages
  • Global
From
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2020 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 1101 Pages
  • Global
From
Primary Biliary Cirrhosis - Pipeline Review, H1 2019 - Product Thumbnail Image

Primary Biliary Cirrhosis - Pipeline Review, H1 2019

  • Drug Pipelines
  • January 2019
  • 128 Pages
  • Global
From
Competitor Landscape: Non-alcoholic Steatohepatitis (NASH) - Product Thumbnail Image

Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)

  • Report
  • November 2018
  • 52 Pages
  • Global
From
Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022 - Product Thumbnail Image

Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022

  • Report
  • December 2022
  • 43 Pages
  • Global
From
Antibiotics Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Thumbnail Image

Antibiotics Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • February 2024
  • 103 Pages
  • Global
From
Viral core protein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Viral core protein inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
FASN Inhibitor Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Application - Product Thumbnail Image

FASN Inhibitor Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Application

  • Report
  • February 2024
  • 118 Pages
  • Global
From
Respiratory Syncytial Virus: Opportunity Analysis and Forecasts to 2028 - Product Thumbnail Image

Respiratory Syncytial Virus: Opportunity Analysis and Forecasts to 2028

  • Report
  • July 2019
  • 170 Pages
  • Global
From
Mitogen Activated Protein Kinase Kinase Kinase 5 - Pipeline Review, H1 2020 - Product Thumbnail Image

Mitogen Activated Protein Kinase Kinase Kinase 5 - Pipeline Review, H1 2020

  • Drug Pipelines
  • February 2020
  • 60 Pages
  • Global
From
Loading Indicator